CRT has been successfully commercialising research reagents created in academic institutes for over 20 years. Our impressive portfolio exceeds 600 monoclonal and polyclonal antibodies as well as cell lines and transgenic mice models.
CRT operates a flourishing Diagnostic and Research Tools business that commercialises research tools such as antibodies, cell lines, transgenics...
Find out more ›CRT has exclusive rights to commercialise reagents arising from Cancer Research UK funded research...
Find out more ›Cell lines will be supplied to you as frozen ampuoles, stored in 20% FCS and 10% DMSO in the relevant growth media...
Find out more ›Our antibodies have not been exhaustively tested in every application of potential interest. If a specific application is not listed, the antibody may still work for this application.
Find out more ›© Cancer Research Technology 2012